Northwest & Ethical Investments L.P. Has $548,000 Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Northwest & Ethical Investments L.P. increased its stake in Teva Pharmaceutical Industries by 151.3%, raising its holdings to 35,679 shares valued at $548,000.
• Teva reported $4.18 billion in quarterly revenue, which was below analyst estimates, but earnings per share of $0.66 beat the consensus estimate by $0.02.
• Several analysts have issued buy ratings on Teva shares, with price targets ranging from $20.00 to $25.00, indicating growing confidence in the company's future performance.

Northwest & Ethical Investments L.P. raised its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 151.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,679 shares of the company's stock after purchasing an additional 21,479 shares during the period. Northwest & Ethical Investments L.P.'s holdings in Teva Pharmaceutical Industries were worth $548,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 5.7% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company's stock worth $38,487,000 after buying an additional 134,705 shares in the last quarter. Financial Sense Advisors Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 63.5% during the first quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company's stock worth $6,231,000 after buying an additional 157,421 shares in the last quarter. King Wealth Management Group increased its holdings in shares of Teva Pharmaceutical Industries by 1,106.9% during the first quarter. King Wealth Management Group now owns 175,000 shares of the company's stock worth $2,690,000 after buying an additional 160,500 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Teva Pharmaceutical Industries by 804.7% in the first quarter. GAMMA Investing LLC now owns 67,474 shares of the company's stock worth $1,037,000 after purchasing an additional 60,016 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 1.2% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company's stock worth $404,775,000 after purchasing an additional 300,000 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $17.5550 on Wednesday. The firm's 50-day moving average price is $16.69 and its 200-day moving average price is $16.25. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80. The firm has a market capitalization of $20.13 billion, a P/E ratio of -109.72, a P/E/G ratio of 1.07 and a beta of 0.62. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. During the same quarter in the prior year, the business earned $0.61 earnings per share. The business's quarterly revenue was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Eric A. Hughes sold 52,742 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Placid Jover sold 6,053 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the sale, the insider owned 6,774 shares in the company, valued at $102,693.84. This represents a 47.19% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 65,001 shares of company stock worth $996,958. Company insiders own 0.55% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on TEVA shares. Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective on the stock. Bank of America upped their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Finally, The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $24.71.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.